Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy.

Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy. Int J Chron Obstruct Pulmon Dis. 2017; 12:135-140.

View in: PubMed

subject areas

Administration, Inhalation
Adrenergic beta-2 Receptor Agonists
Androstadienes
Animals
Benzyl Alcohols
Bronchodilator Agents
Chlorobenzenes
Clinical Trials as Topic
Drug Combinations
Glucocorticoids
Humans
Lung
Muscarinic Antagonists
Pulmonary Disease, Chronic Obstructive
Quinuclidines
Recovery of Function
Research Design
Treatment Outcome

authors with profiles

Chitra Lal
Charlie B. Strange